KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges
Cancers · 27.08.2025 · 17 (17) · 2803
DOI: 10.3390/cancers17172803 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.08.2025. Verfasst von Pietro Paolo Vitiello und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, Ospedale Molinette, 10126 Turin, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AIRC post-doc fellowship for Italy 2024, FONDAZIONE AIRC under 5 per Mille 2018, AIRC under IG 2023.
Abstract (Originalsprache)
KRAS is the most frequently mutated oncogene in cancer. Its activating mutations are associated with aggressive tumor behavior and resistance to certain therapies, including anti-EGFR treatments in colorectal cancer. In particular, the KRAS G12C mutation, which accounts for approximately 3–4% of colorectal cancers (CRCs) and 12–14% of non-small cell lung cancers (NSCLCs), involves a cysteine substitution at codon 12. This has provided the opportunity to develop selective covalent inhibitors that trap the mutant protein in its inactive state. The first targeted therapies for KRAS G12C-mutant cancers comprise sotorasib and adagrasib, both of which have been authorized for use in patients with previously treated NSCLC and CRC. Nevertheless, despite the evidence of clinical activity for this class of agents, primary and acquired resistance, dose optimization, and toxicity management remain significant open challenges. In this review, we summarize recent advances in KRASG12C tumor biology and pharmacological targeting. We also provide additional insights to guide future efforts to overcome the limitations of the current approaches and implement the treatment of KRASG12C-mutant cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, Ospedale Molinette, 10126 Turin, Italy.
- IFOM ETS, The AIRC Institute of Molecular Oncology, 20139 Milan, Italy.
- Molecular Biotechnology Center (MBC), Department of Oncology, University of Turin, 10126 Turin, Italy.
- Pathology Unit, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy.
- Molecular Pathology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
- Pathology Unit, Department of Medical Sciences, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy.
ORCID-Profile: Paola Cassoni, Mauro Papotti, Alberto Bardelli, Massimo Di Maio
Förderung
- AIRC post-doc fellowship for Italy 2024
- FONDAZIONE AIRC under 5 per Mille 2018
- AIRC under IG 2023
- European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme
- European Union—Next Generation EU
Zitieren
APA
Vitiello, P. P., Valsecchi, A. A., Duregon, E., Di Celle, P. F., Cassoni, P., Papotti, M., Bardelli, A., & Di Maio, M. (2025). KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges. Cancers, 17(17), 2803. https://doi.org/10.3390/cancers17172803
Vancouver
Vitiello PP, Valsecchi AA, Duregon E, Di Celle PF, Cassoni P, Papotti M, et al. KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges. Cancers. 2025;17(17):2803. doi:10.3390/cancers17172803
BibTeX
@article{Vitiello2025,
author = {Vitiello, Pietro Paolo and Valsecchi, Anna Amela and Duregon, Eleonora and Di Celle, Paola Francia and Cassoni, Paola and Papotti, Mauro and Bardelli, Alberto and Di Maio, Massimo},
title = {KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2803},
doi = {10.3390/cancers17172803}
}
EUVIMED